PetVivo Holdings, Inc.

PETV
About the company

PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.

Country: United StatesPrice: $0.51Market Cap: $19.5M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

1 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2954 (Top 95.4%)PASSFAILFAILFAILFAILFAILFAILPASSFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-06-29

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-06-29

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-06-29

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-06-29

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-06-29

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio8.4x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-46.1%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-46.1%, ROC=-1240.3%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share8.4x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-54.0%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-31.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=8.4x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($0.51)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-50.02%; #5050/6340 (top 79.7%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.0694; #4902/6449 (top 76.0%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share8.47x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.0605; #4520/5247 (top 86.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-31.29%; #3669/4519 (top 81.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-32.15%; #4504/6202 (top 72.6%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-10.0M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-6.1M
      ✗LynchPositive and growing
      Operating Cash Flow$-6.1M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-170.75%, ROA=-292.83%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-31.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/10 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-33.1%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/14 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-6.1M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-31.29%; #3669/4519 (top 81.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Profitability6% pass✓ 4✗ 31▾

      15 of 16 flag PETV's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/17 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/17 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-711.7%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-793.9% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-10.0M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-720.9%
      ✗Lynch> 15%
      EBIT / Enterprise Value-46.1%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-46.1%, ROC=-1240.3%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-292.83%
      ✗PiotroskiROA > 0
      ROA Change YoY-89.93% -> -292.83% (delta: -202.89%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-170.75%, ROA=-292.83%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY87.8% -> 66.1%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-827.3%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-720.9%
      ✗Dreman> 12%
      Margin of SafetyP/B=8.4x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-757.5% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/16 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-747.0%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-720.9%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-1096.4% (2023) -> -793.9% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 89.5% -> 66.1%, operating margin -1096.4% -> -793.9%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-50.02%; #5050/6340 (top 79.7%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+29.64%; #1456/3702 (top 39.3%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-720.89%; #5122/5226 (top 98.0%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-1.2727; #5342/5884 (top 90.8%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/9 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Growth13% pass✓ 4✗ 9▾

      7 of 8 flag PETV's growth — Graham, Lynch, Dreman +4 more

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -14.7% vs Rev: -9.5%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/16 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth5.6%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 89.5% -> 66.1%, operating margin -1096.4% -> -793.9%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR146.4%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency13% pass✓ 2✗ 9▾

      7 of 8 flag PETV's efficiency — Graham, Buffett, Greenblatt +4 more

      Current Ratio0.72
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-14790.9%
      ✗Buffett> 10%
      ROIC - WACC-14800.9%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-1240.3%
      ✗Greenblatt> 25%
      Current Ratio Change YoY1.30 -> 1.35
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.12x -> 0.32x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities0.72
      ✗Dreman> 1.5
      Return on Invested Capital-380.5%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-1187.7%; FY2024: ROIC=-140.3%; FY2025: ROIC=-284.0%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -284.0%)
      ✗SleepROIC > 12% in a majority of years
    • Verdicts13% pass✓ 2✗ 14▾

      Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #2954✓PiotroskiPASS (F-Score 4)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #2328/2370 (Top 98.2%))✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage33% pass✓ 6✗ 9▾

      8 of 12 flag PETV's debt & leverage — Graham, Buffett, Lynch +5 more

      Debt Levels0.35
      ✓MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.35, IC: -9.3x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.35
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.72
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0.35
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Interest Coverage & Debt/EBITDAIC=-9.3x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.35
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.3513; #2134/4210 (top 50.7%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($19.5M)
    Revenue: $1.1M+0.8% YoY
    Net Income: $10.5M-24.7% YoY

    Financial Snapshot

    Operating Margin-793.9%
    Return on Equity-476.2%
    Debt / Equity0.15
    Current Ratio1.35
    EPS (Diluted)$-0.38
    Shares Retired−47.0% / −110.2% 2y

    Shareholder Return

    Fiscal 2025

    Issued 47.0% of shares last year, 110.2% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-06-30

    2025-07-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, capex.

    Q1 FY 2027

    2026-04-01 – 2026-06-30

    Sources
    FY 2025
    Sources
    • 10-K · 2026-06-29
    FY 2024
    Sources
    • 10-K · 2025-07-10
    FY 2023
    Sources
    • 10-K · 2025-07-10
    FY 2022
    Sources
    • 10-K · 2023-06-29
    FY 2021
    Sources
    • 10-K · 2022-06-24
    Market Cap$19.5Mcurrent--$35.1Mest.$19.5Mest.$21.1Mest.$29.0Mest.$12.8Mest.
    Revenue$1.2M↓10%$337.6K↑13%$1.1M↑1%$1.1M↑17%$968.7K↑6%$917.2K↑693%$115.6K
    Operating Income-$8.8M↓12%-$1.6M↑13%-$9.1M↓13%-$8.1M↑24%-$10.6M↓22%-$8.7M↓73%-$5.1M
    Net Income-$9.8M↓13%-$1.6M↑30%-$10.5M↓25%-$8.4M↑23%-$11.0M↓26%-$8.7M↓74%-$5.0M
    EPS (Diluted)--$-0.05↑44%$-0.38↑7%$-0.41↑47%$-0.78↑8%$-0.85--
    Gross Margin67.0%↓18%66.2%↑5%66.1%↓25%87.8%↓2%89.5%↑18%75.9%↑203%-74.0%
    Operating Margin-747.0%↓24%-476.6%↑23%-793.9%↓12%-711.3%↑35%-1096.4%↓15%-952.2%↑78%-4374.7%
    ROE-720.9%↓210%—-476.2%↓139%-199.1%↑88%-1597.1%↓33%-1202.4%↓1335%-83.8%
    Total Debt$476.5K↑5965%$476.5K↑5965%$321.4K↑1%$318.3K↑1451%$20.5K↓25%$27.4K↓19%$33.8K
    Shareholders' Equity$1.4M↓64%$1.4M↓64%$2.2M↓48%$4.2M↑515%$686.0K↓5%$725.0K↓88%$6.0M
    Current Ratio0.72↓49%0.72↓49%1.35↑4%1.30↑76%0.74↓25%0.98↓83%5.76
    Debt / Equity0.35↑16585%0.35↑16585%0.15↑94%0.08↑152%0.03↓21%0.04↑569%0.01
    Operating Cash Flow-$5.4M-$965.8K↑41%-$6.1M↓15%-$5.3M↑28%-$7.4M↓9%-$6.8M↓63%-$4.2M
    Free Cash Flow---$978.1K-$6.1M↓14%-$5.4M↑30%-$7.7M↓7%-$7.2M↓67%-$4.3M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    PETV vs Peers — Financial Grading

    Revenue$1.1MBottom 25%
    Net Income$10.5MBottom 25%
    ROE-476.2%Bottom 25%
    D/E0.15Top 25%
    Op. Margin-793.9%Bottom 25%
    Curr. Ratio1.35Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11